



**HAL**  
open science

# Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenia: a retrospective study of 152 patients

Damien Fayard

► **To cite this version:**

Damien Fayard. Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenia: a retrospective study of 152 patients. Human health and pathology. 2021. dumas-03482818

**HAL Id: dumas-03482818**

**<https://dumas.ccsd.cnrs.fr/dumas-03482818v1>**

Submitted on 16 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



UNIVERSITÉ CLERMONT AUVERGNE  
UFR DE MÉDECINE ET DES PROFESSIONS PARAMÉDICALES

THÈSE D'EXERCICE

pour le

DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

par

FAYARD Damien, Pierre

Présentée et soutenue publiquement le 27/09/2021

**Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenia: a retrospective study of 152 patients.**

Directeur de thèse : Monsieur RUIVARD Marc, Professeur, CHU Clermont-Ferrand (Médecine Interne - Estaing)

Président du jury : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand

Membres du jury :

- Monsieur SCHMIDT Jeannot, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur TOURNILHAC Olivier, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur ANDRE Marc, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur MANIA Alexandre, Praticien Hospitalier, service de Médecine Interne du CH Henri Mondor d'Aurillac





UNIVERSITÉ CLERMONT AUVERGNE  
UFR DE MÉDECINE ET DES PROFESSIONS PARAMÉDICALES

THÈSE D'EXERCICE

pour le

DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

par

FAYARD Damien, Pierre

Présentée et soutenue publiquement le 27/09/2021

**Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenia: a retrospective study of 152 patients.**

Directeur de thèse : Monsieur RUIVARD Marc, Professeur, CHU Clermont-Ferrand (Médecine Interne - Estaing)

Président du jury : Monsieur RUIVARD Marc, Professeur, UFR de Médecine et des Professions paramédicales de Clermont-Ferrand

Membres du jury :

- Monsieur SCHMIDT Jeannot, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur TOURNILHAC Olivier, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur ANDRE Marc, Professeur, UFR de Médecine et des professions paramédicales de Clermont-Ferrand
- Monsieur MANIA Alexandre, Praticien Hospitalier, service de Médecine Interne du CH Henri Mondor d'Aurillac



## UNIVERSITE CLERMONT AUVERGNE

---

PRESIDENTS HONORAIRES  
UNIVERSITE D'AUVERGNE

: **JOYON** Louis  
: **DOLY** Michel  
: **TURPIN** Dominique  
: **VEYRE** Annie  
: **DULBECCO** Philippe  
: **ESCHALIER** Alain

PRESIDENTS HONORAIRES  
UNIVERSITE BLAISE PASCAL

: **CABANES** Pierre  
: **FONTAINE** Jacques  
: **BOUTIN** Christian  
: **MONTEIL** Jean-Marc  
: **ODOUARD** Albert  
: **LAVIGNOTTE** Nadine

PRESIDENT DE L'UNIVERSITE et  
PRESIDENT DU CONSEIL ACADEMIQUE PLENIER  
PRESIDENT DU CONSEIL ACADEMIQUE RESTREINT  
VICE-PRESIDENTE DU CONSEIL D'ADMINISTRATION  
VICE-PRESIDENT DE LA COMMISSION DE LA RECHERCHE  
VICE-PRESIDENTE DE LA COMMISSION DE LA  
FORMATION ET DE LA VIE UNIVERSITAIRE  
DIRECTEUR GENERAL DES SERVICES

: **BERNARD** Mathias  
: **DEQUIEDT** Vianney  
: **FOGLI** Anne  
: **HENRARD** Pierre  
: **PEYRARD** Françoise  
: **PAQUIS** François



## UFR DE MEDECINE ET DES PROFESSIONS PARAMEDICALES

DOYENS HONORAIRES

: **DETEIX** Patrice  
: **CHAZAL** Jean

DOYEN  
RESPONSABLE ADMINISTRATIVE

: **CLAVELOU** Pierre  
: **ROBERT** Gaëlle

## **LISTE DU PERSONNEL ENSEIGNANT**

### **PROFESSEURS HONORAIRES :**

MM. BACIN Franck - BEGUE René-Jean - BEYTOUT Jean - BOMMELAER Gilles - BOUCHER Daniel - BUSSIERE Jean-Louis - CANO Noël - CASSAGNES Jean - CATILINA Pierre - CHABANNES Jacques - CHAZAL Jean - CHIPPONI Jacques - CHOLLET Philippe - CITRON Bernard - COUDERT Jean - DASTUGUE Bernard - DAUPLAT Jacques - DECHELOTTE Pierre - DEMEOCQ François - DE RIBEROLLES Charles - DETEIX Patrice - ESCANDE Georges - Mme FONCK Yvette - MM. GENTOU Claude - Mme GLANDDIER Phyllis - MM. IRTHUM Bernard - JACQUETIN Bernard - Mme LAVARENNE Jeanine - MM. LAVERAN Henri - LESOURD Bruno - LEVAI Jean-Paul - MAGE Gérard - MARCHEIX Jean- Claude - MICHEL Jean-Luc - MONDIE Jean-Michel - PHILIPPE Pierre - PLAGNE Robert - PLANCHE Roger - PONSONNAILLE Jean - REY Michel - Mme RIGAL Danièle - MM. ROZAN Raymond - SCHOEFFLER Pierre - SIROT Jacques - RIBAL Jean-Pierre - SOUTEYRAND Pierre - TANGUY Alain - TERVER Sylvain - THIEBLOT Philippe - TOURNILHAC Michel - VANNEUVILLE Guy - VIALLET Jean-François - Mlle VEYRE Annie

### **PROFESSEURS EMERITES :**

MM. AUMAITRE Olivier - BOITEUX Jean-Paul - CHAMOUX Alain - DUBRAY Claude - ESCHALIER Alain - KEMENY Jean-Louis - LABBE André - Mme LAFEUILLE Hélène - MM. LEMERY Didier - LUSSON Jean-René

## **PROFESSEURS DES UNIVERSITES-PRATICIENS HOSPITALIERS**

### ***CLASSE EXCEPTIONNELLE***

M. VAGO Philippe	Histologie-Embryologie Cytogénétique
M. AVAN Paul	Biophysique et Traitement de l'Image
M. DURIF Franck	Neurologie
M. BOIRE Jean-Yves	Biostatistiques, Informatique Médicale et Technologies de Communication
M. BOYER Louis	Radiologie et Imagerie Médicale option Clinique
M. POULY Jean-Luc	Gynécologie et Obstétrique
M. CANIS Michel	Gynécologie-Obstétrique
Mme PENAULT-LLORCA Frédérique	Anatomie et Cytologie Pathologiques
M. BAZIN Jean-Etienne	Anesthésiologie et Réanimation Chirurgicale
M. BIGNON Yves Jean	Cancérologie option Biologique
M. BOIRIE Yves	Nutrition Humaine
M. CLAVELOU Pierre	Neurologie
M. GILAIN Laurent	O.R.L.
M. LEMAIRE Jean-Jacques	Neurochirurgie
M. CAMILLERI Lionel	Chirurgie Thoracique et Cardio-Vasculaire
M. DAPOIGNY Michel	Gastro-Entérologie
M. LLORCA Pierre-Michel	Psychiatrie d'Adultes

M.	PEZET Denis	Chirurgie Digestive
M.	SOUWEINE Bertrand	Réanimation Médicale
M.	BOISGARD Stéphane	Chirurgie Orthopédique et Traumatologie
Mme	DUCLOS Martine	Physiologie
M.	SCHMIDT Jeannot	Médecine d'Urgence
M.	BERGER Marc	Hématologie
M.	GARCIER Jean-Marc	Anatomie-Radiologie et Imagerie Médicale
M.	ROSSET Eugénio	Chirurgie Vasculaire
M.	SOUBRIER Martin	Rhumatologie
M.	ABERGEL Armando	Hépatologie
Mle	BARTHELEMY Isabelle	Chirurgie Maxillo-Faciale
M.	RUIVARD Marc	Médecine Interne

***1ère CLASSE***

M.	CAILLAUD Denis	Pneumo-phtisiologie
M.	VERRELLE Pierre	Radiothérapie option Clinique
M.	D'INCAN Michel	Dermatologie -Vénérologie
Mme	JALENQUES Isabelle	Psychiatrie d'Adultes
M.	GERBAUD Laurent	Epidémiologie, Economie de la Santé et Prévention
M.	TAUVERON Igor	Endocrinologie et Maladies Métaboliques
M.	MOM Thierry	Oto-Rhino-Laryngologie
M.	RICHARD Ruddy	Physiologie
M.	SAPIN-DEFOUR Vincent	Biochimie et Biologie Moléculaire
M.	BAY Jacques-Olivier	Cancérologie
M.	COUDEYRE Emmanuel	Médecine Physique et de Réadaptation
Mme	GODFRAIND Catherine	Anatomie et Cytologie Pathologiques
M.	LAURICHESSE Henri	Maladies Infectieuses et Tropicales
M.	TOURNILHAC Olivier	Hématologie
M.	CHIAMBARETTA Frédéric	Ophthalmologie
M.	FILAIRE Marc	Anatomie – Chirurgie Thoracique et Cardio-Vasculaire
M.	GALLOT Denis	Gynécologie-Obstétrique
M.	GUY Laurent	Urologie
M.	TRAORE Ousmane	Hygiène Hospitalière
M.	ANDRE Marc	Médecine Interne
M.	BONNET Richard	Bactériologie, Virologie
M.	CACHIN Florent	Biophysique et Médecine Nucléaire
M.	COSTES Frédéric	Physiologie
M.	FUTIER Emmanuel	Anesthésiologie-Réanimation
Mme	HENG Anne-Elisabeth	Néphrologie
M.	MOTREFF Pascal	Cardiologie
Mme	PICKERING Gisèle	Pharmacologie Clinique
M.	RABISCHONG Benoît	Gynécologie Obstétrique
M.	CHABROT Pascal	Radiologie et Imagerie Médicale
M.	DESCAMPS Stéphane	Chirurgie Orthopédique et Traumatologique
Mme	HENQUELL Cécile	Bactériologie Virologie
M.	POMEL Christophe	Cancérologie – Chirurgie Générale

## 2ème CLASSE

Mme CREVEAUX Isabelle	Biochimie et Biologie Moléculaire
M. FAICT Thierry	Médecine Légale et Droit de la Santé
Mme KANOLD LASTAWIECKA Justyna	Pédiatrie
M. TCHIRKOV Andréï	Cytologie et Histologie
M. CORNELIS François	Génétique
M. LESENS Olivier	Maladies Infectieuses et Tropicales
M. AUTHIER Nicolas	Pharmacologie Médicale
M. BROUSSE Georges	Psychiatrie Adultes/Addictologie
M. BUC Emmanuel	Chirurgie Digestive
M. LAUTRETTE Alexandre	Néphrologie Réanimation Médicale
Mme BRUGNON Florence	Biologie et Médecine du Développement et de la Reproduction
M. ESCHALIER Romain	Cardiologie
M. MERLIN Etienne	Pédiatrie
Mme TOURNADRE Anne	Rhumatologie
M. DURANDO Xavier	Cancérologie
M. DUTHEIL Frédéric	Médecine et Santé au Travail
Mme FANTINI Maria Livia	Neurologie
M. SAKKA Laurent	Anatomie – Neurochirurgie
M. BOURDEL Nicolas	Gynécologie-Obstétrique
M. GUIEZE Romain	Hématologie
M. POINCLOUX Laurent	Gastroentérologie
M. SOUTEYRAND Géraud	Cardiologie
M. EVRARD Bertrand	Immunologie
M. POIRIER Philippe	Parasitologie et Mycologie
Mme PHAM DANG Nathalie	Chirurgie Maxillo-Faciale et Stomatologie
Mme SARRET Catherine	Pédiatrie

## PROFESSEURS DES UNIVERSITES DE MEDECINE GENERALE

### 1ère CLASSE

M. CLEMENT Gilles	Médecine Générale
M. VORILHON Philippe	Médecine Générale

## PROFESSEURS DES UNIVERSITES

### 2ème CLASSE

Mme MALPUECH-BRUGERE Corinne	Nutrition Humaine
------------------------------	-------------------



## PROFESSEURS ASSOCIES DES UNIVERSITES

Mme BOTTET-MAULOUBIER Anne	Médecine Générale
M. CAMBON Benoît	Médecine Générale
M. TANGUY Gilles	Médecine Générale

## MAITRES DE CONFERENCES DES UNIVERSITES - PRATICIENS HOSPITALIERS

### *HORS CLASSE*

Mme CHAMBON Martine	Bactériologie Virologie
Mme BOUTELOUP Corinne	Nutrition
Mme FOGLI Anne	Biochimie Biologie Moléculaire
Mle GOUAS Laetitia	Cytologie et Histologie, Cytogénétique

### *1ère CLASSE*

M. MORVAN Daniel	Biophysique et Traitement de l'Image
Mle GOUMY Carole	Cytologie et Histologie, Cytogénétique
M. MARCEAU Geoffroy	Biochimie Biologie Moléculaire
Mme MINET-QUINARD Régine	Biochimie Biologie Moléculaire
M. ROBIN Frédéric	Bactériologie
Mle VERONESE Lauren	Cytologie et Histologie, Cytogénétique
M. DELMAS Julien	Bactériologie
Mle MIRAND Audrey	Bactériologie Virologie
M. OUCHCHANE Lemlih	Biostatistiques, Informatique Médicale et Technologies de Communication
M. LIBERT Frédéric	Pharmacologie Médicale
Mle COSTE Karen	Pédiatrie
Mle AUMERAN Claire	Hygiène Hospitalière
Mme CASSAGNES Lucie	Radiologie et Imagerie Médicale
M. LEBRETON Aurélien	Hématologie
M. BUISSON Anthony	Gastroentérologie
M. BOUVIER Damien	Biochimie et Biologie Moléculaire
M. MAQDASY Salwan	Endocrinologie, Diabète et Maladies Métaboliques
Mme NOURRISSON Céline	Parasitologie - Mycologie
Mme PONS Hanaë	Biologie et Médecine du Développement et de la Reproduction

**2ème CLASSE**

M. JABAUDON-GANDET Matthieu	Anesthésiologie – Réanimation Chirurgicale
M. COLL Guillaume	Neurochirurgie
M. GODET Thomas	Anesthésiologie-Réanimation et Médecine Péri-Opératoire
M. LACHAL Jonathan	Pédopsychiatrie
M. MOUSTAFA Farès	Médecine d'Urgence

**MAITRES DE CONFERENCES DES UNIVERSITES  
DE MEDECINE GENERALE**

**1ère CLASSE**

Mme VAILLANT-ROUSSEL Hélène	Médecine Générale
-----------------------------	-------------------

**2ème CLASSE**

Mme LAPORTE Catherine	Médecine Générale
-----------------------	-------------------

**MAITRES DE CONFERENCES DES UNIVERSITES**

**HORS CLASSE**

M. BLANCHON Loïc	Biochimie Biologie Moléculaire
M. MARCHAND Fabien	Pharmacologie Médicale
Mme VAURS-BARRIERE Catherine	Biochimie Biologie Moléculaire

**CLASSE NORMALE**

M. BAILLY Jean-Luc	Bactériologie Virologie
Mlle AUBEL Corinne	Oncologie Moléculaire
Mlle GUILLET Christelle	Nutrition Humaine
M. BIDET Yannick	Oncogénétique
M. DALMASSO Guillaume	Bactériologie
M. PIZON Frank	Santé Publique
M. SOLER Cédric	Biochimie Biologie Moléculaire
M. GIRAUDET Fabrice	Biophysique et Traitement de l'Image
M. LOLIGNIER Stéphane	Neurosciences – Neuropharmacologie

Mme MARTEIL Gaëlle  
M. PINEL Alexandre

Biologie de la Reproduction  
Nutrition Humaine

**MAITRES DE CONFERENCES ASSOCIES DES UNIVERSITES**

M. BERNARD Pierre  
Mme ESCHALIER Bénédicte  
Mme RICHARD Amélie  
M. TESSIERES Frédéric  
Mme ROUGE Laure

Médecine Générale  
Médecine Générale  
Médecine Générale  
Médecine Générale  
Médecine Générale

## AUX MEMBRES DU JURY

Au président de ce jury, le Professeur Marc Ruivard, pour m'avoir fait confiance pour réaliser ce travail de thèse et avoir toujours su me prodiguer de bons conseils. Merci pour votre accompagnement attentif et vos encouragements durant ces années. Acceptez ma plus profonde reconnaissance.

Au Professeur Marc André, pour votre soutien sans faille et vos encouragements renouvelés, malgré les doutes croisés en chemin ; pour votre aide précieuse quand il le fallait ; pour la confiance que vous m'accordez à nouveau en m'offrant la chance de travailler et d'apprendre à vos côtés. Veuillez recevoir toute ma gratitude.

Au Professeur Jeannot Schmidt, pour l'honneur que vous me faites en acceptant de juger ce travail avec l'expertise qui est la vôtre, soyez assuré de mon plus profond respect.

Au Professeur Olivier Tournilhac, pour la considération que vous accorderez à ce travail, je vous adresse mes plus sincères remerciements et tout mon respect.

Au Docteur Alexandre Mania, merci d'avoir accepté de siéger dans ce jury pour évaluer mon travail. Merci pour les conseils prodigués à un jeune interne qui ne savait pas tellement où il allait, merci de refermer la boucle.

Au Dr Trouillier, pour m'avoir appris l'humilité ; aux Drs Smets, Olgne, Outh, Le Guenno, Rieu, Grobost, Denis, pour m'avoir appris la médecine chacun à leur façon ; aux Drs Vidal et Letertre, pour les fous rires ; au Dr Garrouste pour sa confiance, à Clémence et Marine pour la folie ; au Dr Bachelier pour sa bonne humeur ; au Dr Senet pour m'avoir tant appris.

Au Dr Hervé Lobbes, qui a été mon premier conseiller, et à qui je dois plus qu'il ne le sait ; merci pour ton oreille attentive et ta bienveillance, sans oublier ton swing impeccable.

Au Dr François Chasset, pour m'avoir enseigné la dermatologie ; merci de m'avoir accordé ta confiance, merci de m'avoir viré tant de fois pour me reprendre ensuite.

Au Pr Olivier Aumaître, pour son soutien discret mais solide, et pour son humour.

Aux co-internes croisés en chemin : Emily mon acolyte du premier jour ; Valentin le chat noir ; Elise et Elodie les dermatojolies ; Dodo qui n'a pas le temps ; Anaïs, Cyril le barde, Clément et Flo les pros du baby, Clara la révolutionnaire, la team parisienne, Alycia, Clot et les autres.

Aux équipes paramédicales, infirmières et aides-soignantes, qui m'ont appris mon métier beaucoup mieux que les livres.

Aux copains du théâtre : Jacques depuis le début, Agathe, Rémy, Roxane, les Marie, Amandine, Lucas, Clémentine, Baptiste, Clémence, Elodie, Béatrice, Valentin et puis les autres ; aux copains de toujours : Coco, Maxime, Wendy, Esther, Victor ; si ma vie était une maison, vous seriez tous les fondations qui la soutiennent et le ciment qui la rend solide. Merci d'exister, ne changez jamais.

À ma famille : à Céline, Fred et Gabrielle ; à mon oncle et ma tante pour leur soutien infaillible depuis toujours ; à Gérard, pour m'avoir élevé comme son fils sans jamais douter ; à ma mère, pour qui les mots ne peuvent suffire, merci pour tout ce que tu m'as donné.

A ma grand-mère et à mon grand-père, partis avant de voir leur petit-fils devenir docteur.

## TABLE OF CONTENTS

<b>1. Introduction</b> .....	<b>14</b>
<b>2. Material and Methods</b> .....	<b>15</b>
2.1 Study design and participants .....	15
2.2 Data collection and definitions .....	15
2.3 Laboratory techniques for APL dosage .....	16
2.4 Statistical analysis .....	17
<b>3. Results</b> .....	<b>18</b>
3.1 Patients characteristics .....	18
3.2 Description of thromboembolic events .....	18
<b>4. Discussion</b> .....	<b>20</b>
<b>5. Conclusion</b> .....	<b>22</b>

## TABLES AND FIGURES

### **TABLES:**

<b>Table I.</b> Baseline characteristics of the population according to APL status .....	23
<b>Table II.</b> Description of 18 patients with thromboembolic events .....	24
<b>Table III.</b> Association between thromboembolic events and APL status .....	26
<b>Table IV.</b> Multivariate analysis for independent factors associated with thrombosis .....	27

### **FIGURE:**

<b>Figure 1.</b> Thrombosis-free survival according to APL status in our ITP cohort .....	26
---	----

## LIST OF ABBREVIATIONS

**aCL** : Anticardiolipin

**APL** : Antiphospholipid Antibodies

**APS** : Antiphospholipid Syndrome

**ASH** : American Society of Hematology

**BMI** : Body Mass Index

**CKD-EPI** : Chronic Kidney Disease - Epidemiology

**IgG, IgM** : Immunoglobulin G, Immunoglobulin M

**HR** : Hazard Ratio

**ITP** : Immune Thrombocytopenic Purpura

**LA** : Lupus Anticoagulant

**MRI** : Magnetic Resonance Imaging

**NSAIDs** : Nonsteroidal Anti-Inflammatory Drugs

**SBP** : Systolic Blood Pressure

**SLE** : Systemic Lupus Erythematosus

**TE** : Thromboembolic Events

**TPO-RA** : Thrombopoietin Receptor Agonists

**VKA** : Vitamin K Antagonist

**VTE** : Venous Thromboembolic Event



## **1. Introduction**

Immune Thrombocytopenic Purpura (ITP) or Immune Thrombocytopenia is an acquired autoimmune condition, defined by thrombocytopenia  $< 100$  G/L, and caused by autoantibodies directed against platelet antigens, as well as impaired platelet production in the bone marrow (dysmegakaryopoiesis) (1).

The main complication associated with ITP is bleeding, but an increased thrombotic risk is also well established in the literature (2-6).

Antiphospholipid antibodies (APL), e.g anticardiolipin (aCL IgG and IgM), anti $\beta$ 2gp1 (IgG and IgM), and lupus anticoagulant (LA), are clearly associated with an increased prevalence of thromboembolic events (TE), especially LA positivity (7-10).

Prevalence of antiphospholipid antibodies in patients with ITP varies between 20 and 40% in several cohorts (11, 12) but their implication in this thrombotic risk is unclear (13-17).

One of the main characteristics of these studies is the exclusion from the study population of the ITP associated with a connective tissue disease (13, 14, 16), even though hematologic systemic lupus erythematosus (SLE) is frequently associated with a positive antiphospholipid status (18).

Finally, most of these studies were conducted before the extended use of TPO-receptor agonists (eltrombopag and romiplostim), of which the association with an increased risk of thrombosis is yet to be determined (19-26).

An increased risk of thrombosis with TPO-RA might exist in patients with antiphospholipid syndrome (APS), or even with antiphospholipid antibodies without any former thrombotic event (18, 20).

With this new monocentric cohort, we aim to specify which role can be attributed to the positivity of antiphospholipid antibodies during ITP, in terms of both thrombotic and bleeding risks (13, 27).

## **2. Material and methods**

### **2.1. Study design and participants**

In this retrospective, monocentric study, we enrolled all ITP out and in-patients seen at least once in a single regional “French competence center” for auto-immune cytopenias between January 1<sup>st</sup>, 2014 and December 31<sup>st</sup>, 2019. In this center, APL serology (anticardiolipin IgG and IgM, anti $\beta$ 2gp1 IgG and IgM, lupus anticoagulant) was systematically performed in all patients with ITP.

Patients were included if they had a diagnosis of ITP according to the 2011 ASH criteria (1). Patients with an associated connective tissue disorder were not excluded.

Patients under 16 years of age or with a diagnosis of ITP secondary to malignant hemopathy or neoplasm, myelodysplastic syndrome, chronic viral infection, and acute ITP were excluded from the analysis.

### **2.2. Data collection and definitions**

Demographic data recorded included gender and age at diagnosis, last known BMI, cardiovascular risk factors (e.g diabetes, hypertension, active smoking), the presence of a connective tissue disorder. We also recorded the platelet count at diagnosis and platelet count nadir during follow-up, median duration of follow-up, antiphospholipid status, and maximal bleeding score during follow-up (28).

Response to corticotherapy (complete response, partial response, and no response, according to the ASH 2011 criteria), and use of TPO-RA were also collected.

For patients with at least one episode of arterial or venous thromboembolic event (VTE), delay between ITP diagnosis and thrombosis was recorded, as well as platelet count at the time of the event (when available), and thrombotic risk factors (e.g for arterial thromboses: age, active smoking, dyslipidemia, diabetes, hypertension; for venous thromboses: active cancer, central venous catheter, recent surgery (<3 months), immobilization (bed rest) > 3 days, sepsis, splenectomy, estroprogestative contraception, pregnancy or post-partum, BMI>30, known thrombophilia (apart from APS), and a previous venous event) (29, 30).

Thromboembolic events had to be objectively confirmed (e.g ultrasonography, computed tomography, or MRI).

For patients with at least one bleeding episode with a Khellaf score greater than or equal to 8, classic bleeding risk factors were recorded (e.g medication such as NSAIDs, platelet aggregation inhibitors, VKA, direct anticoagulants, heparin); cranial trauma or previous ischemic stroke for cranial hemorrhage; hepatic failure defined by a factor V <60%; chronic kidney disease defined by a CKD-EPI < 30 mL/minute; uncontrolled hypertension defined by a SBP > 160 mmHg; chronic alcoholic intoxication defined by more than 30g of pure alcohol per day for a man, 20g/day for a woman; recent surgery at the bleeding site) (31).

### 2.3. Laboratory techniques for APL detection

APL positivity (LA, and/or anticardiolipin IgG and/or IgM, and/or anti $\beta$ 2gp1 IgG and/or IgM) was confirmed at 12 weeks in most of our cases, according to "Sydney" guidelines (32).

Lupus anticoagulant positivity was defined by the International Society on Thrombosis and Haemostasis (33).

Detection of anticardiolipin and anti $\beta$ 2gp1 antibodies was performed using a chemiluminescent technique (HemosIL AcuStar (WERFEN)).

Cut-off values were determined according to a Fontana study (34). We considered positivity for anticardiolipin and anti $\beta$ 2gp1 when values were equal to or greater than twice the upper limit.

#### 2.4. Statistical analysis

Continuous data were expressed as mean and standard deviation or median and extreme values. The assumption of normality was assessed with the Shapiro-Wilk test. Comparisons between groups (i.e., APL-negative vs. APL-positive) were carried out, for quantitative data, using Student t-test or non-parametric Mann-Whitney test, when the assumptions of t-test were not met. The homoscedasticity was studied using Fisher-Snedecor test. For categorical data, chi-squared or Fisher's exact test were applied. Thrombosis free survival was treated as censored data and estimates were constructed using the Kaplan-Meier method. The log-rank test was used for univariate analysis to test the prognostic value of patient characteristics for the occurrence of event (i.e., thrombosis). Cox proportional hazards regression was used to investigate associated prognostic factors in multivariable analyses. Hence, no specific statistical strategy approach, such as stepwise, was conducted. The covariates were chosen with caution due to sample size according to the univariate results and to clinical relevance (35). Particular attention was paid to multicollinearity. The proportional-hazard hypothesis was verified using Schoenfeld's test and plotting residuals. Results were expressed as hazard-ratio (HR) with a confidence interval of 95%. Statistical analysis was performed using Stata

software version 15 (StataCorp, College Station, US). Statistical tests were two-sided with a type-I error set at 5%.

### **3. Results**

#### **3.1. Patients characteristics**

We included 152 patients, of whom 91 (59.8%) were female, with a mean age at ITP diagnosis of 50,5 years. They were followed for a mean period of 105 months, representing 1331 patient-years. Patients characteristics according to the APL status are detailed in table I: 25/152 (16,4%) patients were positive for at least 1 APL. There was no significant difference between the two groups, except for the association with a connective tissue disease which was significantly higher in the APL+ group (44% vs 17,4%), and the percentage of patients treated with corticosteroids which was higher in the APL-negative group (81% vs 60%).

Thirty-one patients had an associated connective tissue disease: SLE (7 in the APL+ group, 2 in the APL- group), Gougerot-Sjögren syndrome (4 in the APL- group), Evans syndrome (2 in the APL+ group, 9 in the APL- group), dermatomyositis (1 in the APL- group), systemic sclerosis (1 in the APL+ group), rheumatoid arthritis (3 in the APL- group), primary biliary cirrhosis (2 in the APL- group).

Only a few patients underwent splenectomy, without any significant difference between APL-positive and APL-negative patients.

#### **3.2. Description of thromboembolic events**

Among our population, 18 patients developed 20 thromboembolic events (12 arterial events and 8 venous events). One patient developed a catastrophic antiphospholipid syndrome 108 months after the diagnosis of ITP. One patient developed obstetrical APS, which we

considered to be an arterial event. For every patient, clinical and biological characteristics at baseline and at the time of the thrombotic event are shown in table II.

The incidence rate of TE events in the whole ITP population was 1.5/100 patient-years, and for the APL-positive group 3.2/100 patient-years, versus 0.92/100 patient-years for the APL-negative group.

TE events were observed in 8/25 (32%) APL-positive patients, and in 10/127 (8%) APL-negative patients (HR 5.94; CI95% 2.22-15.9); this difference was statistically significant (table III). We compared the thrombosis-free survival of APL-positive patients with APL-negative patients by using a Kaplan-Meier test (fig.1): after 10 years of follow-up, survival rate was 68% in the APL-positive group versus 94% in the APL-negative group, a difference that was statistically significant.

When comparing the different APL, LA positivity and aCL positivity were both associated with thrombotic events in univariate analysis, but anti $\beta$ 2gp1 positivity was not. However, in a multivariate model, only aCL positivity seemed independently associated with thrombosis. This result is to be considered with caution, because of the high degree of multicollinearity between aCL and LA positivity.

We also separated the thromboembolic events between arterial (12 patients) and venous events (7 patients); the difference between the two groups remained significant on both arterial and venous events in univariate analysis (table III).

A multivariate analysis adjusted on confounding factors (connective tissue disease, smoking status, diabetes, and high blood pressure for arterial events; connective tissue disease,

splenectomy, and smoking status for venous events) showed that the difference between the two groups was still significant for arterial events, but not for venous events (table IV).

When we compared the 18 patients with thrombosis according to their APL status, there was no significant difference between the two groups, regarding mean age, mean platelet count at the time of thrombosis, or response to corticosteroids (data not shown, cf table II).

#### **4. Discussion**

We found higher incidence of thrombosis in patients with APL, especially arterial events. The global incidence of thrombosis in our cohort was 11.8%, which is slightly higher than what is reported in the literature (2, 36).

LA and aCL positivity were both associated with thrombotic events, confirming what was already shown in previous studies (13, 15, 17), but we failed to demonstrate that each APL was independent from the other.

In our study, the prevalence of APL was 16.4%, which was slightly less than usually described in the literature (11, 13, 14).

One of the innovative points of this study is the inclusion of patients treated with TPO-RA (35% of our patients), who were absent from previous studies because their widespread use in ITP is quite recent, and most of these studies date back to the early 2010s. We showed that the prescription of TPO-RA was not associated with an increased risk of thrombosis in our cohort, but they tended to be less prescribed in APL-positive patients, which is the population that might have an increased risk of thrombosis when receiving such treatment (18).

Our study has several limitations, the first one being its retrospective nature which predisposes to selection and misclassification biases. However, we tried to avoid these biases

by systematically excluding every patient with incomplete and/or uncertain data and including only those who had a regular follow-up. The second major limitation is due to the small number of thrombotic events, which did not allow statistical significance on several analyses.

We must also consider the higher prevalence of connective tissue disease among APL-positive patients, which can be considered as a bias since SLE and rheumatoid arthritis are independently associated with a higher risk of venous thrombosis (37-38). However, in our multivariate analysis, the thrombotic risk associated with APL was independent from the SLE status (cf table IV).

There were also more smokers in the APL-positive group (28% vs 12.5%), an association already suggested in some studies (39-40) and that could have artificially increased the thrombotic risk in APL-positive patients; but this association was not found in the multivariate analysis.



## 5. Conclusion

Our results showed that APL positivity during ITP was associated with a higher risk of thrombosis, irrespective of other traditional risk factors. On the other hand, the frequency and severity of bleeding events was not influenced by APL status. Therefore, our suggestion would be to perform APL serology in every ITP patient, to determine a category of patients with a higher risk of thrombotic event. In this population, thromboprophylaxis with aspirin could be discussed, provided the platelet count is greater than 50 G/L. Further large-scale prospective studies are required to address these questions and provide guidelines on how to manage these high-risk patients.

**Le Doyen de l'UFR de Médecine,**



**Le Président du Jury,**

*A Clermont-Ferrand, le 29 Juillet 21*

CHU de CLERMONT-FERRAND  
MEDECINE INTERNE - CHU ESTAING  
Professeur Marc RUIVARD  
N° A.D.E.L.I. : 63 10 4570 5  
N° RPPS : 10001275246  
Tél. : 04.73.750.085 - Fax : 04.73.750.361

A handwritten signature in black ink, located to the right of the stamp.

**Table I. Baseline characteristics of the population according to APL status**

	<b>APL-positive (n=25)</b>	<b>APL-negative (n=127)</b>	<b>p-value</b>
<b>Demographic and clinical characteristics</b>			
Mean age at diagnosis (years) (+/- SD, years)	46.9 (+/-19.8)	51.2 (+/- 20.4)	0.34
Female sex, <i>n</i> (%)	15 (60)	76 (59.8)	0.99
BMI (kg/m <sup>2</sup> ), median (extreme)	24.5 (18-35)	25 (17-42)	0.38
Follow-up (months), median (extreme)	90 (23-558)	69 (13-378)	0.38
Bleeding event, <i>n</i> (%)	13 (52)	80 (63)	0.31
Khellaf score > 8 °, <i>n</i> (%)	5 (38.5)	31 (38.7)	0.98
Associated connective tissue disease	10 (40)	21 (16.5)	<b>0.008</b>
<b>Cardiovascular risk factors, <i>n</i> (%)</b>			
Active smoking at last follow-up	7 (28)	16 (12.5)	0.07
Diabetes	3 (12)	19 (15)	0.70
High blood pressure	8 (32)	44 (34.6)	0.80
<b>Biological features</b>			
Platelet count at diagnosis (G/L), mean (+/- SD)	44.4 (+/-29.4)	41 (+/-31.7)	0.65
Platelet nadir (G/L), mean (+/- SD)	26.2 (+/-23.4)	21.3 (+/-23)	0.19
Lupus anticoagulant, <i>n</i> (%)	14 (56)	--	
Anticardiolipin (IgG and/or IgM), <i>n</i> (%)	16 (64)	--	
Antiβ2gp1 (IgG and/or IgM), <i>n</i> (%)	17 (68)	--	
Triple positivity, <i>n</i> (%)	7 (28)	--	
<b>Treatment characteristics</b>			
Any treatment, <i>n</i> (%)	18 (72)	104 (81.8)	0.26
Corticosteroids, <i>n</i> (%)	15 (60)	103 (81.1)	<b>0.02</b>
TPO-R agonists, <i>n</i> (%)	5 (20)	49 (38.6)	0.08
Corticosteroid efficacy*, <i>n</i> (%)	13 (86.7)	76 (73.8)	0.35
Splenectomy, <i>n</i> (%)	2 (8)	9 (7.1)	1.00

° among the 93 bleeding events

\* including partial response (platelet count ≥ 30G/L and at least 2-fold increase the baseline count and absence of bleeding) and complete response (platelet count ≥ 100 G/L and absence of bleeding)

**Table II. Description of 18 patients with thromboembolic events**

Pt	Age at TE (years)	Sex	Plt at diagnosis	LA	aCL	aβ2gp1	Treatment	Response to CS	Thrombotic risk factors	Type of TE	Months after ITP diagnosis	Plt
1	68	M	2	-	-	-	CS + IVIg + ELT	CR	Age HL, past smoking, age	NSTEMI	83	259
2	74	M	80	-	-	-	CS + D + RTX	CR		Stroke	31	45
3	24	F	68	-	-	-	CS + RTX	CR	COCP	DVT (iliac)	65	140
4	81	F	35	-	+	-	0	-	Obesity	PE	0	35
5	53	M	17	-	-	-	CS + IVIg + D + ELT + RTX	CR	HL, age, past smoking, TPO-RA	TIA	5	43
6	87	M	4	+	-	-	CT + D + ELT	CR	Age, TPO-RA	STEMI	8	135
7	30	F	70	+	+	+	CS	CR	0	Obstetrical APS (fetal death)	1	69
8	54	M	17	-	-	-	CS + D + RTX + splenectomy + ELT + IVIg	CR	5 days after splenectomy	DVT (splenic vein)	226	ND
9	26	F	81	+	+	+	0	-	0	Stroke	13	56
10	74	M	41	-	+	-	CT + D + ELT + RPM	CR	Age	Stroke	56	46
11	67	M	60	-	-	-	CS	CR	Age, HL	TIA	232	88
12	28	F	16	+	+	+	0	-	Post-partum (<1 month), obesity (IMC 31)	CAPS (STEMI, spleen and kidney infarction, cerebral venous thrombosis)	105	278
13	66	M	70	-	-	-	CS	NR	Age, HL	STEMI	106	ND
14	47	M	48	+	-	-	CS + IVIg + RTX	PR	0	PE	101	35
15	55	M	45	+	+	-	RTX	-	Age, past smoking	Stroke	26	ND
16	86	M	92	-	-	-	CS + IVIg + ELT	NR	0	PE	0	37


17	67	M	50	-	-	-	CS + IVIg + RPM + RTX + D + ELT + MMF	NR	Age, past smoking, TPO-RA	TIA	80	355
18	66	F	3	-	-	-	CT + IVIg + D + RTX + Vincristine + splenectomy + ELT + RPM	NR	Obesity (IMC 37), splenectomy	DVT PE	15 26	166 1

**aβ2gp1 : anti-bêta2-gp1 IgG and/or IgM; aCL : anticardiolipin IgG and/or IgM; COCP : combined oral contraceptive pill; CR : complete response; CS : corticosteroids; D : dapsone; ELT : eltrombopag; HL : hyperlipidemia; IVIg : intravenous immunoglobulins; LA : lupus anticoagulant; MMF : mycophenolate mofetil; NR : no response; Plt : platelet count; PR : partial response; Pt : patient; RPM : romiplostim; RTX : rituximab; TE : thromboembolic event; TIA : transient ischemic attack**

**Table III. Association between thromboembolic events and APL status**

	APL- positive (n=25)	APL-negative (n=127)	HR (CI 95%)	p-value
<b>Any thromboembolic event (n=18 patients), n (%)</b>	8 (32)	10 (7.9)	5.94 (2.22-15.9)	<b>&lt;0.001</b>
<b>Venous thromboembolic event (n=7 patients), n (%)</b>	3 (12)	4 (3.1)	5.89 (1.19-29.3)	<b>0.03</b>
<b>Arterial thromboembolic event* (n=12 patients), n (%)</b>	6 (24)	6 (4.7)	7.24 (2.21-23.8)	<b>0.001</b>

\* total of VTE + ATE = 19 because one patient presented with CAPS and both arterial and venous thrombosis (myocardial, splenic, kidney infarction, and cerebral venous sinus thrombosis); we also included obstetrical APS (n=1) in arterial events



**Figure 1. Thrombosis-free survival according to APL status in our ITP cohort**

**Table IV. Multivariate analysis for independent factors associated with thrombosis****A. All thrombotic events**

Variables	HR (95% CI)	Beta coefficient	P-value
APL positivity	7.15 (2.52-20.24)	3.71	<b>&lt;0.0001</b>
Connective tissue disease	0.82 (0.23-2.84)	-0.31	0.75
Active smoking	1.08 (0.28-4.21)	0.12	0.91
Diabetes	1.12 (0.27-4.71)	0.16	0.87
High blood pressure	1.12 (0.35-3.56)	0.19	0.85
TPO-RA	1.97 (0.66-5.84)	1.22	0.223

**B. Arterial events**

Variables	HR (95% CI)	Beta coefficient	P-value
APL positivity	7.86 (2.25-27.50)	3.23	<b>0.001</b>
Connective tissue disease	0.85 (0.19-3.73)	-0.21	0.83
Active smoking	0.84 (0.16-4.27)	-0.21	0.83
Diabetes	1.42 (0.26-7.68)	0.41	0.68
High blood pressure	1.05 (0.25-4.34)	0.07	0.95

**C. Venous events**

Variables	HR (95% CI)	Beta coefficient	P-value
APL positivity	4.90 (0.86-27.8)	1.79	0.07
Connective tissue disease	1.00 (0.15-6.48)	0.00	1.00
Splenectomy	2.81 (0.30-26.25)	0.91	0.36
Active smoking	2.24 (0.35-14.28)	0.86	0.39

## References

1. Neunert C, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011 Apr 21;117(16):4190–207.
2. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. 1. 2010 Jul 1;95(7):1167–75.
3. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. *British Journal of Haematology*. 2011;152(3):360–2.
4. Nørgaard M, Severinsen MT, Mæggbæk ML, Jensen AØ, Cha S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. *British Journal of Haematology*. 2012;159(1):109–11.
5. Ito S, Fujiwara S, Ikeda T, Toda Y, Mashima K, Umino K, et al. Evaluation of thrombotic events in patients with immune thrombocytopenia. *Ann Hematol*. 2020 Jan 1;99(1):49–55.
6. Le Guenno GL, Guieze R, Audia S, Khellaf M, Michel M, Bonnotte B, et al. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. *Internal Medicine Journal*. 2019;49(9):1154–62.
7. Devreese KMJ. Antiphospholipid antibodies: Evaluation of the thrombotic risk. *Thrombosis Research*. 2012 Oct 1;130:S37–40.
8. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood*. 2003 Mar 1;101(5):1827–32.
9. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *The Lancet Neurology*. 2009 Nov 1;8(11):998–1005.
10. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. *Lupus*. 2014 Dec 1;23(14):1468–76.

11. Uthman I, Godeau B, Taher A, Khamashta M. The Hematologic Manifestations of the Antiphospholipid Syndrome. *Blood Reviews*. 2008 Jul 1;22(4):187–94.
12. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and Clinical Significance of Elevated Antiphospholipid Antibodies in Patients With Idiopathic Thrombocytopenic Purpura. *Blood*. 1994 Dec 15;84(12):4203–8.
13. Despujol CP-D, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. *British Journal of Haematology*. 2008;142(4):638–43.
14. Yang Y-J, Yun G-W, Song I-C, Baek S-W, Lee K-S, Ryu H, et al. Clinical Implications of Elevated Antiphospholipid Antibodies in Adult Patients with Primary Immune Thrombocytopenia. *The Korean journal of internal medicine*. 2011 Dec 1;26:449–54.
15. Kim K-J, Baek I-W, Yoon C-H, Kim W-U, Cho C-S. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. *British Journal of Haematology*. 2013;161(5):706–14.
16. Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. *Journal of Thrombosis and Haemostasis*. 2014;12(8):1266–73.
17. Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. *Autoimmunity Reviews*. 2016 Mar 1;15(3):203–9.
18. Guitton Z, Terriou L, Lega J-C, Nove-Josserand R, Hie M, Amoura Z, et al. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. *Rheumatology*. 2018 Aug 1;57(8):1432–8.
19. Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, et al. Thromboses sous agonistes du récepteur de la thrombopoïétine au cours du purpura thrombopénique immunologique. Étude rétrospective multicentrique en France. *La Revue de Médecine Interne*. 2017 Mar 1;38(3):167–75.
20. Catalá-López F, Corrales I, de la Fuente C, Bermejo D, Martín-Serrano G, Montero D, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with



thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. *Medicina Clínica (English Edition)*. 2015 Dec 1;145:511–9.

21. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. *The Lancet*. 2008 Feb 2;371(9610):395–403.

22. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. *New England Journal of Medicine*. 2010 Nov 11;363(20):1889–99.

23. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. *British Journal of Haematology*. 2013;161(3):411–23.

24. Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. *British Journal of Haematology*. 2019;185(3):503

25. Rodeghiero F, Stasi R, Giagounidis A, Viallard J-F, Godeau B, Pabinger I, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. *European Journal of Haematology*. 2013;91(5):423–36.

26. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Guo DM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). *Journal of Thrombosis and Haemostasis*. 2010;8(6):1372–82.

27. Cruz ACL, Colella MP, De Paula EV, Annichinno-Bizzachi J, Orsi FA. Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies. *European Journal of Internal Medicine*. 2019 Nov 1;69:e6–7.

28. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. *Haematologica*. 2005 Jan 1;90(6):829–32.

29. Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015 Aug;12(8):464.

30. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. *Journal of Thrombosis and Haemostasis*. 2013;11(1):116–23.
31. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey. *Chest*. 2010 Nov 1;138(5):1093–100.
32. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *Journal of Thrombosis and Haemostasis*. 2006;4(2):295–306.
33. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. *Journal of Thrombosis and Haemostasis*. 2009;7(10):1737–40.
34. Fontana P, Poncet A, Lindhoff-Last E, Moerloose P de, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. *Journal of Thrombosis and Haemostasis*. 2014;12(12):2034–7.
35. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. *American Journal of Epidemiology*. 1989 Jan 1;129(1):125–37.
36. Machin N, Ragni MV, Comer DM, Yabes JG. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study. *Thrombosis Research*. 2018 Dec 1;172:80–5.
37. Chung W-S, Lin C-L, Chang S-N, Lu C-C, Kao C-H. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. *Journal of Thrombosis and Haemostasis*. 2014;12(4):452–8.
38. Chung W-S, Peng C-L, Lin C-L, Chang Y-J, Chen Y-F, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. *Annals of the Rheumatic Diseases*. 2014 Oct 1;73(10):1774–80.
39. Binder SR, Litwin CM. Anti-phospholipid Antibodies and Smoking: An Overview. *Clinic Rev Allerg Immunol*. 2017 Aug;53(1):1–13.
40. Gustafsson JT, Gunnarsson I, Källberg H, Pettersson S, Zickert A, Vikerfors A, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. *Annals of the Rheumatic Diseases*. 2015 Aug 1;74(8):1537–43.

**(Conseil national de l'ordre des médecins)**

**SERMENT D'HIPPOCRATE**

Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.

Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.

Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité.

J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences.

Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences.

Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.

Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.

Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque.

Nom, Prénom

Signature

## SERMENT D'HIPPOCRATE

En présence des Maîtres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité dans l'exercice de la Médecine.

Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail. Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les mœurs ni à favoriser le crime.

Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.

Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque.

Nom, Prénom

Signature

**Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenia: a retrospective study of 152 patients.**

**Abstract:**

**CONTEXT** Immune thrombocytopenia (ITP) is associated with both bleeding and thrombotic events. Antiphospholipid antibodies (APL) are frequently found during ITP, but their involvement in this increased thrombotic risk is still debated.

**OBJECTIVES** We conducted an observational retrospective monocentric study to evaluate the bleeding and thrombotic risks associated with APL positivity in ITP.

**METHODS** One hundred and fifty-two patients diagnosed with ITP were retrospectively included in our study, with a mean follow-up of 105 months. ITP associated with connective tissue diseases such as systemic lupus were not excluded. ITP related to neoplasia, myelodysplastic syndrome of chronic viral infection were excluded. Conventional risk factors for venous and arterial events were collected.

**RESULTS** Twenty-five patients (16.4%) were positive for at least 1 APL. The frequency and severity of bleeding events were not influenced by APL status. Eighteen patients (11.8%) developed 20 thromboembolic events, with a Hazard ratio of APL-positive to APL-negative patients for thrombosis was 7.15 (95% confidence interval 2.52-20.24), after adjusting for confounding factors. The arterial risk was superior to the venous risk.

**CONCLUSION** APL positivity in ITP is frequent and associated with a higher risk of venous and arterial thrombotic events. Systematic screening of APL status in ITP seems useful to identify patients at high-risk to experience thrombosis.

**Keywords :**

- Immune thrombocytopenia
- Thrombosis
- Antiphospholipid antibodies
- Venous thrombosis
- Arterial thrombosis
- Thrombopoietin receptor agonist